RNAi & antisense oligonucleotide drug platforms
Short chemically modified nucleic acids that switch down gene transcripts, with delivery by GalNAc or lipid nanoparticles — commercial, with the first siRNA drug (patisiran) approved in 2018.
1 · What it gives
RNAi and antisense (ASO) platforms use short chemically modified nucleic acids to target and modulate gene transcripts through base pairing, offering a programmable route to targets that small molecules and antibodies miss. They replace or augment conventional chemical and antibody drugs. The industry is commercial with multiple approved drugs: the first siRNA drug, patisiran, was approved in 2018.
2 · What it replaces 6
| D1 | Enteric methane from cattle and sheep reduced by bromoform-containing red seaweed (Asparagopsis), essential-oil and plant-extract feed additives, and low-methane genetics — instead of unabated emissions and synthetic inhibitors alone Replaces: Unabated enteric methane; reliance on the synthetic inhibitor 3-nitrooxypropanol (3-NOP) as the only approved tool; ionophore antibiotics … | FEED |
| D2 | Bumblebee pollination instead of hormone sprays and manual vibration in greenhouse tomatoes Replaces: Fruit-setting hormone sprays (synthetic auxins such as 4-CPA / tomatotone) and labour-intensive manual flower vibration in greenhouse … | MACRO |
| D2 | Detergent enzymes for low-temperature washing instead of phosphates, extra surfactant and hot washing Replaces: Phosphate builders (STPP), part of the fossil-based surfactant load, and high wash temperatures (60–90 °C) needed to remove protein, starch … | CHEM |
| D2 | Disease-resistant crop varieties (marker-assisted breeding, stacked resistance genes, cisgenesis) instead of routine fungicide spray programmes Replaces: Season-long protective fungicide programmes on susceptible varieties — e.g. 10–20 sprays of mancozeb/chlorothalonil/metalaxyl against potato … | SEED |
| D1 | Durable wood without toxic preservatives — furfurylated wood (from agricultural residues), acetylated wood, thermally modified wood, naturally durable species and constructive protection — instead of CCA, creosote and biocidal impregnation Replaces: Chromated copper arsenate (CCA), creosote (coal-tar), pentachlorophenol (PCP), copper-azole and other biocidal wood preservatives for … | BUILD |
| D1 | Feed enzymes (phytase) and fermentation amino acids instead of inorganic phosphate and excess crude protein Replaces: Dicalcium phosphate / rock-phosphate P supplements in pig and poultry feed; excess soybean-meal crude protein (ammonia, nitrate pollution); … | FEED |
3 · How to implement 4 steps
- 1Sequence screeningScreen sequences.
- 2Chemical modificationModify chemically for stability.
- 3Delivery formulationFormulate with a delivery system such as GalNAc or LNPs.
- 4Preclinical and INDRun preclinical evaluation and file an IND.
4 · Who delivers
Matched suppliers (matched automatically)
| Huaheng Biology 华恒生物 (SSE 688639) | China | Producer | active |
| Liselo Labs | South Africa | Research / RTO | active |
| Absolute | India | Not classified | active |
| Agricultural Research Council (ARC) | South Africa | Research / RTO | active |
| Alliance of Bioversity International and CIAT | Colombia | Research / RTO | active |
| BBCA Group 丰原集团 | China | Research / RTO | active |
| COFCO Biotechnology 中粮科技 (SZ 000930) | China | Research / RTO | active |
| CONICET | Argentina | Research / RTO | active |
| Cathay Biotech 凯赛生物 (SSE 688065) | China | Producer | active |
| GenScript ProBio / Genscript | China | Research / RTO | active |
| Geno | United States | Producer | acquired |
| Green Biologics Ltd. | United Kingdom | Producer | dissolved |
Leading companies and institutes (from the brief)
Ionis Pharmaceuticals and Alnylam Pharmaceuticals are named as prominent global providers. Others are matched by the portal under Pharma & biologics and Advanced therapies.
5 · Rules & route to market
state registration within 45 working days after acceptance of documents (plus dossier and tests)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
The FDA provides oversight in the US; guidelines are evolving to address how oligonucleotides differ from small molecules.
European Union
The EMA provides oversight in the EU (and the PMDA in Japan).
China
The sources reviewed on 2026-10-16 identified no China regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.
6 · Money: tenders & grants
| Tender | Czechia – Immunosuppressive agents – Selektivní Imunosupresiva - Eculizumab IV. Institut klinické a experimentální medicíny · Czechia | Oct 20, 2026 4 days |
| Tender | Czechia – Immunosuppressive agents – Takrolimus 1x denně - LP ADVAGRAF Institut klinické a experimentální medicíny · Czechia | Oct 20, 2026 4 days |
| Tender | Netherlands – Influenza vaccines – Trivalent Influenza Vaccines 2026 Rijksinstituut voor Volksgezondheid en Milieu (RIVM), RIVM · Netherlands | Oct 19, 2026 3 days |
| Grant | Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the … National Institutes of Health · United States | Aug 18, 2027 306 days |
| Grant | Development of cell-free protein synthesis platforms for discovery and/or production of biologicals European Commission · EU | Apr 13, 2027 179 days |
| Grant | First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States | Oct 15, 2027 364 days |
7 · Tech stack & innovations
Main risks from the sources: off-target effects, tissue-specific delivery, immune activation and high production cost.
Sources 4
- Cell.com — www.cell.com 2026-10-16
- Cn healthcare.com — www.cn-healthcare.com 2026-10-16
- Sciencedirect.com — www.sciencedirect.com 2026-10-16
- Pmc.ncbi.nlm.nih.gov — pmc.ncbi.nlm.nih.gov 2026-10-16